Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Runncoach you said, “Could we get a little more specific? “ I'm not sure if that was a reply to my post or the PR.
I get the feeling that the lack of specificity from the company about how they are going to use the funds is because they have a strategic plan that they are not ready to let us know about yet. They will spring it closer to this summer. This is my hope.
A possibly irrelevant old question about the last trial. The company decided that is wanted to “fail fast” and not extend the previous trial. How could they make that decision if the data was blinded?
Alzy B, just curious, how long have you been following this gem? How did you find out about it? Hope you don’t mind me asking.
Runncoach, I don’t know if I should be ashamed of picking your brain like a buzzard:) But thanks man, I appreciate you.
I hope that all of the Alzheimer’s trials out there are successful. Although, I selfishly wish that they will hold off until NTRP strikes first and I can take my profits. That being said, are there any opinions on how the success or failure of the trials due for release before NTRP will affect our stock price in the short term?
Could there be a private placement put together, between the investors that want to sell a large block of shares and a big buyer that wants to get in without raising the price in the open market?
We have a dilutive market cap of about $100 million. It will be much higher before results are released. Wasn’t it around $250 million before last release?
It's still too soon for many investors. I predict the share price will be over $6 in May.
Yes, patience is the key here. I am up to my balls in NTRP shares, but I’m not worried. I am very confident that the price will be much higher before the results are released, giving me time to take some off the table. If another company comes out with positive results before our release, our stock will take a hit, but that's ok it will be a good thing for mankind.
Who's selling down here? This is below the price before it when up. The take down seems so orderly, predictable and may be coordinated. Is it the investors now selling for a small loss, while keeping the warrants?
Do you know of any other company's AD trial results release due out before our third quarter release?
Can you remember where you got this breakdown of individual patient results from?
Would Bryostatin's current supply issues temporarily hold back the stock price if positive results are released in 6 months?
What can we, on this board, do to stress to the company the points you just made? Can we come up with a strategy?
No other drug options, huge demand, we have a low market cap. If this trial is successful the m/c won’t move pass $1billion, it will shoot pass $1billion!
Runncoach, I asked Michael Meltzer, a member/admin at Bio Trades a Facebook group to check out NTRP. He is a prolific stock researcher. He said he would. I also mentioned your name as a person to chat with to get up to speed.
I just posted about NTRP on a Facebook group I’m in call Bio Traders. They have about 1600 members. We must all do our share:)
Antti, I like the way you think. You want to take a stab at what you think the share price will be before results are released? Last time it spiked to almost $30 before being shorted down to around $18.
I agree with you. Healthcare is desperate for an affective AD drug. If this trial duplicates the previous non-memantine results what do you think the market cap will be.
I agree that you shouldn’t use money you can’t afford to lose. Other than a failed trial, what other scenarios would wipe-out positions in this stock?
I placed a couple of 1200 plus shares buy orders yesterday. They both went through quickly in one transaction each. I'm use to multiple transactions to fill an order, maybe in 100 share increments. Does this mean there is a big seller out there?
Well at lease no one is shorting the stock.
Did someone have a low stop-lost placed and got their shares stolen?
Not that it matters at this point, but was there any break down of the individual patient baseline and ending cognitive scores released in the last trial? Wondering rather Bryostatin works better on the moderate or severe AD patients.
By the company raising cash so early before the results, either they have immediate need for it or they did it early so that they can raise again closer to results.
How many other companies are going after treating the moderate to severe AD patients? I'm sure not many if any. That alone sure set a premium on NTRP.
Runncoach, do you think there's a chance of another cash raise dilution before the readout of the results.
My strategy this go round is similar to yours. I'm getting in early heavy and will take some off the table as we get closer to results. I've learned from the last time.
I've been thinking through low bar senarios.
In these trial results what separation would we need from placebo to be reconsider a success, 4 or 5 SIB points?
Too late now, but I think the trial should have been extended by 3 months. In the previous trial looks like the placebo group did better than expected, but we all know that with more time the mental decline would have accelerated. But in the Bryostatin arm the trajectory was very encouraging.
I lost big two years ago on NTRP, but I am still a believer. I like what I see. If these results confirm the ph2 what conservatively do you think the s/p will increase to.
With the 2 years I was factoring in if the drug remained non-oral, which would make it a little more inconvenient. Looking at the the trajectory of the non-mamentine chart I like our chances.
What do you think the lowest bar of achievement for Bryostatin in AD patients to be considered a successful drug. I think if it can prevent a mental decline for 2 years the drug is good as gold.
Runncoach, I'm trying to catch up on the company. Where can I find the newer released updated information the company published on the previous trial? Thanks.
Still very cheap. Thanks Cyosol.
What is the diluted market cap of NTRP? Anyone knows? Thanks.
I realize that the 40ug dose won't be used going forward, but I am looking at it's results to help predict the chances of success of the the 20ug in the text trial. If the 40ug scores had consistently gone down, I could understand that, but the up, down,up, down scores are confusing. Also what may have caused the big drop from week 13 to 15 in those 40ug non-memantine pts? Just trying to understand the forces of down regulation vs memantine free.
I wish I had a better understanding of the 40 mcg results in the non-memantine arm. It seemed very erratic.
Runncoach, how much of the trial results do you think the company currently have? All 17 weeks?
Is it the norm to release results that early in the morning 6:30am? I think they want to give investors more time to digest what they just read.
I think the weekend would give the AF-kind of shorts more time to coordinate and write a lot of misinformation type of articles.
You're joking right? SP only goes up to 25-30 if results are good. Can I take a puff? Lol